

## Progesterone microinjections into the pontine reticular formation modify sleep in male and female rats

Ignacio Camacho-Arroyo<sup>a,\*</sup>, Rosa Hernández-Gollas<sup>a</sup>, Joaquín Manjarrez<sup>b</sup>,  
Raúl Alvarado<sup>b</sup>

<sup>a</sup>Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, Mexico, D.F. Mexico

<sup>b</sup>Unidad de Investigaciones Cerebrales, Instituto Nacional de Neurología y Neurocirugía MVS, Mexico, D.F. Mexico

Received 29 March 1999; accepted 26 April 1999

---

### Abstract

It has been reported that progesterone ( $P_4$ ) induces changes in sleep, but the brain regions involved in these actions are unknown. We studied the effects of  $P_4$  microinjections into the pontine reticular formation (PRF) upon rat sleep. Intact adult male and ovariectomized female rats were unilaterally injected with  $P_4$  into the PRF and the sleep-waking cycle was recorded for 6 h.  $P_4$  (1.0 and 5.0  $\mu\text{g}/0.2 \mu\text{l}$ ) did not modify sleep, but at a higher dose (7.5  $\mu\text{g}/0.2 \mu\text{l}$ ) it produced a marked decrease in rapid eye movement sleep (REM) latency in both male (55%) and female (63%) rats. A non-significant increase in the number of REM episodes was observed after  $P_4$  administration. These findings suggest that  $P_4$  should participate in the mechanisms related to REM initiation in the rat through its effects in the PRF. © 1999 Elsevier Science Ireland Ltd. All rights reserved.

**Keywords:** Progesterone; Pontine reticular formation; Steroids; Rapid eye movement sleep; Sleep-waking cycle; Brain stem

---

Progesterone ( $P_4$ ) participates in several functions of the central nervous system (CNS) [1].  $P_4$  produces both short and long-term changes in the function of neurons and glial cells through different mechanisms that involve the interaction of this steroid with intracellular specific progesterone receptors (PR), modulatory sites located in neurotransmitter receptors and ionic channels [16]. By these mechanisms  $P_4$  regulates neuronal excitability and the expression of various genes in the brain. It has also been reported that many effects of  $P_4$  in the CNS are due to its reduced metabolites [5,18].

It has been shown that  $P_4$  possesses hypnogenic properties in mammals [8]. Rapid eye movement sleep (REM) latency diminishes during the luteal phase of the woman menstrual cycle when  $P_4$  levels are high [15], whereas slow-wave sleep (SWS) decreases before menses when  $P_4$  levels are low [9]. Sleep-spindles in women also change during the menstrual cycle [10] and the sleep pattern clearly varies across the three trimesters of pregnancy [3,6]. In adult men  $P_4$  administration diminishes SWS latency and increases Stage 2 sleep [8].

During the estrous cycle of the rat a reduction in nocturnal SWS and REM was observed on proestrus day. Both sleep phases are increased during pseudopregnancy in rats when  $P_4$  levels are elevated [19]. The systemic administration of  $P_4$  to male rats decreases both the amount of wakefulness (W) and the latency of SWS [13]. The brain regions involved in sleep-waking cycle changes induced by  $P_4$  are unknown. Therefore, in order to gain an insight into the regions responsible of the effects of  $P_4$  on sleep, we evaluated sleep-waking cycle after microinjections of this hormone into the pontine reticular formation (PRF), a key region in the regulation of sleep-waking cycle of the rat [4,7]. Since systemic administration of  $P_4$  can modify sleep in both sexes, we decided to evaluate the effects of this steroid both in intact males and in ovariectomized females whose  $P_4$  levels are very low and do not exhibit the variations observed during the estrous cycle [11].

Adult Wistar rats of both sexes (230–260 g) were used in the study. Female animals were bilaterally ovariectomized under ketamine (Rhoné Merieux, Querétaro, México) anesthesia (80 mg/kg, i.p.) 15 days before electrodes implantation for sleep recordings. Electrodes were surgically implanted in all rats under anesthetic conditions as mentioned above. Stainless-steel electrodes were implanted in the frontal and parietal cortices for electroencephalo-

---

\* Corresponding author. Tel.: +525-622-3098; fax: +525-616-2010.

E-mail address: igcar@servidor.unam.mx (I. Camacho-Arroyo)

Table 1

Effects of P<sub>4</sub> microinjections into the PRF on the sleep-waking cycle of the male rat<sup>a</sup>

	Sham injection	Vehicle (0.2 µl)	P <sub>4</sub> (7.5 µg/0.2 µl)
<b>W</b>			
Percentage	30.6 ± 5.3	30.9 ± 5.4	29.7 ± 3.8
Number	31.3 ± 4.9	38.3 ± 2.2	41.0 ± 5.1
Mean duration	4.0 ± 0.7	3.1 ± 0.7	2.9 ± 0.5
<b>SWS</b>			
Percentage	67.7 ± 5.1	66.7 ± 5.4	67.8 ± 3.7
Number	34.7 ± 4.7	41.3 ± 1.6	47.8 ± 3.5
Mean duration	8.0 ± 1.1	6.1 ± 0.4	5.2 ± 0.4
Latency	16.9 ± 4.6	14.3 ± 2.8	12.3 ± 5.2
<b>REM</b>			
Percentage	1.7 ± 0.6	2.4 ± 0.7	2.5 ± 0.7
Number	5.0 ± 0.9	5.2 ± 0.8	8.0 ± 1.2
Mean duration	1.1 ± 0.2	1.6 ± 0.4	1.0 ± 0.1
Latency	127.3 ± 35.0	123.6 ± 19.5	57.1 ± 11.6**

<sup>a</sup> Values are the means ± SEM of six adult intact animals during 6 h of recording. Percentage of each phase refers to the total recorded time. Mean duration of each phase and latency are given in minutes. \*\**P* < 0.05 compared with sham injection and vehicle (propylenglycol).

graphic (EEG) recording, and in the orbital cavity for electrooculographic (EOG) recording. Electrodes were also inserted into the neck muscles to record the electromyogram (EMG). Besides, a stainless-steel guide cannula (21-gauge) was unilaterally implanted into the PRF 4 mm above the injection site (AP: -9.3, L: 1.2, V: 9.2) [17].

After surgery the animals were allowed 5 days to recover in their home-cage with food and water ad libitum, in a 12:12 h light/dark cycle with lights on at 07:00 h. During the following 5 days they were habituated to the recording conditions. Once the habituation period was completed, six rats of each sex were unilaterally injected with 1.0, 5.0 and 7.5 µg of P<sub>4</sub> (Steraloids, Pauling, NY) in a total volume of 0.2 µl using an injection needle (27-gauge) inserted into the guide cannula connected through a polyethylene tube to a 5 µl Hamilton syringe. The sleep study was carried out for 3 consecutive days: on day 1 of the experiment a baseline sleep recording was performed following a sham injection procedure (just insertion of the needle but no injection). On day 2 the animals were randomly injected with vehicle (propylenglycol) or with P<sub>4</sub>. On day 3 the animals previously injected with vehicle received P<sub>4</sub> while those which had received the hormone were injected with vehicle. Immediately after each injection (at 08:00 h) a polygraphic recording was performed for 6 h. The records of the sleep-waking cycle were analyzed visually by a scorer blind to the treatments following established criteria for W (mixed-frequency, low voltage EEG, variable eye movements and high neck EMG), SWS (low-frequency, high voltage EEG, sleep spindles, scarce eye movements and medium muscle tone), and REM (mixed-frequency, low voltage EEG, rapid eye movements and low EMG neck tonus).

At the end of the third recording, Direct blue (Sigma) (1.2 µg/0.2 µl) was injected in order to localize the injection site. When the sleep study was completed animals were injected with an overdose of sodium pentobarbital and transcardially perfused with saline and 3.7% formalin. The brains were removed and postfixed in 3.7% formalin. The injection sites were verified in 80 µm coronal slices by using the atlas of Paxinos and Watson [17].

We evaluated latency (in the case of sleep phases), percentage, number of episodes and mean duration of W, SWS and REM. Repeated measures analysis of variance and post-hoc Student's *t*-test were used for statistical evaluation. Probability values were calculated by using the Prism 2.01 program (Graph Pad, CA).

P<sub>4</sub> microinjections into the PRF (1.0 and 5.0 µg/0.2 µl) did not modify sleep-waking cycle (data not shown) but at a higher dose (7.5 µg/0.2 µl) produced a marked decrease in the latency to REM in male (55%) and female (63%) rats as compared with the vehicle. P<sub>4</sub> did not modify the percentage or the duration of this sleep phase (Tables 1 and 2). Interestingly, a tendency towards an increase in the number of REM episodes both in males (55%) and females (39%), compared with the vehicle, was also observed with the highest dose of P<sub>4</sub>; although these changes were not statistically significant (Tables 1 and 2). Neither W nor SWS was affected by P<sub>4</sub>.

All P<sub>4</sub> microinjections were located in the nucleus reticularis pontis caudalis (Fig. 1) of the PRF [17]. Although slight differences were noticed in the injection sites, the electrographic recording of the animals was similar in all cases.

Our results suggest that P<sub>4</sub> should be involved in REM

Table 2

Effects of P<sub>4</sub> microinjections into the PRF on the sleep-waking cycle of the female rat<sup>a</sup>

	Sham injection	Vehicle (0.2 µl)	P <sub>4</sub> (7.5 µg/0.2 µl)
<b>W</b>			
Percentage	25.5 ± 2.8	27.9 ± 2.5	20.4 ± 1.0
Number	26.7 ± 3.7	25.7 ± 2.1	25.7 ± 4.6
Mean duration	4.1 ± 1.1	4.2 ± 0.5	3.5 ± 0.7
<b>SWS</b>			
Percentage	69.7 ± 2.7	67.7 ± 2.4	73.3 ± 1.8
Number	34.2 ± 4.0	32.0 ± 2.0	35.8 ± 4.0
Mean duration	8.1 ± 1.1	8.1 ± 0.6	7.9 ± 0.7
Latency	15.6 ± 4.5	22.0 ± 3.8	11.1 ± 4.2
<b>REM</b>			
Percentage	4.8 ± 0.5	4.3 ± 0.5	6.1 ± 1.0
Number	10.2 ± 1.3	8.5 ± 1.2	11.8 ± 1.6
Mean duration	1.8 ± 0.2	1.9 ± 0.1	1.9 ± 0.1
Latency	116.5 ± 18.2	83.8 ± 9.3	43.5 ± 6.1**

<sup>a</sup> Values are the means ± SEM of six ovariectomized animals during 6 h of recording. Percentage of each phase refers to the total recorded time. Mean duration of each phase and latency are given in minutes. \*\**P* < 0.05 compared with sham injection and vehicle (propylenglycol).




Fig. 1. Location of  $P_4$  ( $7.5 \mu\text{g}/0.2 \mu\text{l}$ ) microinjection sites in the PRF of male (●) and female (△) rats. Schemes and coordinates were taken from the atlas of Paxinos and Watson [17]. Two injections were located in each marked site. All sites corresponded to the nucleus reticularis pontis caudalis.

regulation through its effects in the PRF. The reduction of REM latency observed during the luteal phase of the woman menstrual cycle [15] when  $P_4$  levels are high is in line with our data since we found that  $P_4$  microinjections into the PRF markedly diminishes REM latency in rats. This reduction as well as the tendency towards an increase in the number of REM episodes after  $P_4$  administration suggest that this steroid hormone in the PRF should be involved in the regulation of REM initiation but not in its maintenance. In addition, that percentage or duration of REM was not affected by  $P_4$ .

$P_4$  induced very similar effects both in male and female rats suggesting that the mechanisms involved in the regulation of REM by  $P_4$  at the PRF level are similar in both sexes. Although all the injections were located in the nucleus reticularis pontis caudalis of the PRF (Fig. 1), the possibility that the induction of REM by  $P_4$  could be due to the activation of other regions such as the nucleus reticularis pontis oralis, produced by the diffusion of the hormone from the injection site cannot be discarded and deserves further investigation.

In contrast with our results, a delay in REM latency after the administration of high doses of  $P_4$  ( $180 \text{ mg/kg}$ , i.p.) was reported in male rats [13]. This difference could be due to both the doses and the route of administration of the hormone. It is also possible that  $P_4$  modulates REM initiation through different pathways in the brain.

Interestingly, it has been shown that the systemic administration of  $P_4$  to male rats produces, like benzodiazepines, both an increase in pre-REM and a reduction in SWS latency [13]. However, we did not find any  $P_4$  effect upon SWS. These different effects could be due to the doses used in both studies. It would be interesting to assess the effect of

higher doses of  $P_4$  in PRF and other brain areas upon sleep-waking cycle of the rat.

The mechanisms involved in the induction of REM by  $P_4$  in the PRF are unknown.  $P_4$  effects may be produced through its interaction with PR and the subsequent activation of specific genes in the PRF. This may be supported by a recent report which indicates the presence of PR in brain stem reticular formation of the rat [12].

Possibly,  $P_4$  effects on REM latency may not be directly produced by the hormone but indirectly through its A-ring reduced metabolites such as  $5\alpha$ - and  $5\beta$ -pregnanolone, which possess hypnogenic properties [13,14]. Hitherto  $P_4$  metabolism in the PRF is unknown and deserves further investigation. The effects of  $P_4$  on REM may be mediated through the activation of cholinergic neurotransmission in the PRF since there is extensive information about the key role of acetylcholine in the initiation and maintenance of REM [2]. The knowledge of the role of  $P_4$  in cholinergic neurotransmission regulation in the PRF could be determinant in elucidating the mechanisms involved in the induction of REM by  $P_4$ .

In conclusion, our data indicate that the PRF is involved in the induction of REM by  $P_4$  in both male and female rats.

We thank Flora García-Formentí from CELE, Universidad Nacional Autónoma de México (UNAM) for the revision of the English manuscript. This work was supported by PAIP grant, Facultad de Química, UNAM.

- [1] Baulieu, E.E., Schumacher, M., Koenig, H., Jung-Testas, I. and Akwa, Y., Progesterone as a neurosteroid: actions within the nervous system. *Cell. Mol. Neurobiol.*, 16 (1996) 143–154.
- [2] Bourgin, P., Escourrou, P., Gaultier, C. and Adrien, J., Induction of rapid eye movement sleep by carbachol infusion into the pontine reticular formation in the rat. *NeuroReport*, 6 (1995) 532–536.
- [3] Brunner, D.P., Münch, M., Biedermann, K., Huch, R., Huch, A. and Borbély, A.A., Changes in sleep and sleep electroencephalogram during pregnancy. *Sleep*, 17 (1994) 576–582.
- [4] Camacho-Arroyo, I., Alvarado, R., Manjarrez, J. and Tapia, R., Microinjections of muscimol and bicuculline into the pontine reticular formation modify the sleep-waking cycle in the rat. *Neurosci. Lett.*, 129 (1991) 95–97.
- [5] Camacho-Arroyo, I., Pasapera, A.M., Pérez-Palacios, G. and Cerbón, M.A., Progesterone and its metabolites in the functions of the central nervous system. *Rev. Invest. Clin.*, 47 (1995) 329–340.
- [6] Driver, H.S. and Shapiro, C.M., A longitudinal study of sleep stages in young women during pregnancy and postpartum. *Sleep*, 15 (1992) 449–453.
- [7] Friedman, L. and Jones, B.E., Computer graphics analysis of sleep-wakefulness state changes after pontine lesions. *Brian Res. Bull.*, 13 (1984) 53–68.
- [8] Friess, E., Tagaya, H., Trachsel, L., Holsboer, F. and Rupperecht, R., Progesterone-induced changes in sleep in male subjects. *Am. J. Physiol.*, 272 (1997) E885–E891.
- [9] Ho, A., Sex hormones and sleep of women. *Sleep Res.*, 1 (1972) 184.
- [10] Ishizuka, Y., Pollak, C.P., Shirakawa, S., Kakuma, T., Azumi,

- K., Usui, A., Shiraishi, K., Fukuzawa, H. and Kariya, T., Sleep spindle frequency changes during the menstrual cycle. *J. Sleep Res.*, 3 (1994) 26–29.
- [11] Jussofie, A., Körner, I., Schell, C. and Hiemke, C., Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. *Exp. Clin. Endocrinol.*, 103 (1995) 196–204.
- [12] Kastrup, Y., Amandusson, A., Hallbeck, M., Hirata, S., Hermanson, O. and Blomqvist, A., Localization of progesterone receptor mRNA and progesterone receptor-like immunoreactivity in the rat brain stem. *Soc. Neurosci. Abstr.*, 24 (1998) 1853.
- [13] Lancel, M., Faulhabber, J., Holsboer, F. and Rupperecht, R., Progesterone induces changes in sleep comparable to those of agonistic GABA<sub>A</sub> receptor modulators. *Am. J. Physiol.*, 271 (1996) E763–E772.
- [14] Lancel, M., Faulhabber, J., Schiffelholz, T., Romeo, E., Di Michele, F., Holsboer, F. and Rupperecht, R., Allopregnanolone affects sleep in a benzodiazepine-like fashion. *J. Pharmacol. Exp. Ther.*, 282 (1997) 1213–1218.
- [15] Lee, K.A., Shaver, J.F., Giblin, E.C. and Woods, N.F., Sleep patterns related to menstrual cycle phase and premenstrual affective symptoms. *Sleep*, 13 (1990) 403–409.
- [16] Mahesh, V.B., Brann, D.W. and Hendry, L.B., Diverse modes of action of progesterone and its metabolites. *J. Steroid Biochem. Mol. Biol.*, 56 (1996) 209–219.
- [17] Paxinos, G. and Watson, C., *The Rat Brain in Stereotaxic Coordinates*, Academic Press, New York, 1986.
- [18] Rupperecht, R., Hauser, C.A., Trapp, T. and Holsboer, F., Neurosteroids: molecular mechanisms of action and psychopharmacological significance. *J. Steroid Biochem. Mol. Biol.*, 56 (1996) 163–168.
- [19] Zhang, S.Q., Kimura, M. and Inoué, S., Sleep patterns in cyclic and pseudopregnant rats. *Neurosci. Lett.*, 193 (1995) 125–128.